February 2018 Issue of MMM
There was so much bigger-picture coverage of pharma and healthcare in 2017 - pricing, Affordable Care Act reform and repeal - that it was easy ...
It was at an MM&M event back in late 2013 that I got my first glimpse of how this industry feels about big data.
Read the February 2018 issue in its entirety.
In the past, pharma hasn't used data effectively to engage its A-list HCPs. Five companies hope to change that.
Fueled by system-wide demand and facilitated by AI, the industry's lofty expectations around real-world evidence could soon be fulfilled
We asked some of the agency world's sharpest data people to answer a pair of questions about the future of data in and around pharma ...
Four data aces share their backgrounds, inspirations, and guiding philosophies
Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.
More has been written about millennials — and their healthcare habits — than about any other generation. Here, Gen Y marketers explain why most of ...
Zero people have such tales about Robert Leverte, which is why news of his pending induction into the Medical Advertising Hall of Fame was received ...
Sigurdsson is charged with leading the agency's digital offering to meet growing client demand.
At a time when value-based healthcare is a more common objective among stakeholders, EHR data can enable collaboration among payers, providers, health systems, and pharma ...
FDA Commissioner Dr. Scott Gottlieb has been saying all the right things regarding digital health.
For some, the term machine learning may conjure up images of virtual assistants or automated tools.
Rather than talking at them, we need to design with and for them.
At Work With
The VP of market access at Mitsubishi Tanabe Pharma America discusses driving access and bringing to market the first FDA-approved ALS drug in years.
By allowing companies to claim a 50% tax credit for qualified clinical testing expenses, developing drugs for rare diseases became economically feasible for the first ...